BioSpace

Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial

Extending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.

By BioSpace

1 min read
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights